Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSJ-110 in Allergic Conjunctivitis
NCT04622345Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VSJ-110 in allergic conjunctivitis (AC), sponsored by Vanda Pharmaceuticals Inc.. Started Nov 2020; status: completed.
02
Drugs
VSJ-110
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04622345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622345.